Evidence map›Paper›PMID 34960727›Full record

ArticleViruses2021

The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.

Iris Maria Forte, Paola Indovina, Serena Montagnaro, Aurora Costa, Carmelina Antonella Iannuzzi, Francesca Capone, Rosa Camerlingo, Anna Maria Malfitano, Francesca Pentimalli, Gianmarco Ferrara and 4 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Iris Maria ForteCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.ORCID 0000-0001-9490-5844
Paola IndovinaInstitute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), 80131 Naples, Italy.
Serena MontagnaroDepartment of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.ORCID 0000-0001-5569-8774
Aurora CostaDepartment of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Carmelina Antonella IannuzziCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.
Francesca CaponeExperimental Pharmacology Unit-Laboratories of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura deiTumori "Fondazione G. Pascale", 80131 Naples, Italy.
Rosa CamerlingoCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.ORCID 0000-0001-6488-9740
Anna Maria MalfitanoDipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.ORCID 0000-0002-6193-2835
Francesca PentimalliCell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.ORCID 0000-0003-4740-6801
Gianmarco FerraraDepartment of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.
Massimiliamo QuintilianiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Giuseppe PortellaDipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.ORCID 0000-0001-8276-9769
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.ORCID 0000-0002-5959-016X
Roberto CiarciaDepartment of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Naples Federico II · ITUniversity of Siena · ITInstitute for High Performance Computing and Networking · ITUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma (MM) is an aggressive asbestos-related cancer, against which no curative modalities exist. Oncolytic virotherapy is a promising therapeutic approach, for which MM is an ideal candidate; indeed, the pleural location provides direct access for the intra-tumoral injection of oncolytic viruses (OVs). Some non-human OVs offer advantages over human OVs, including the non-pathogenicity in humans and the absence of pre-existing immunity. We previously showed that caprine herpesvirus 1 (CpHV-1), a non-pathogenic virus for humans, can kill different human cancer cell lines. Here, we assessed CpHV-1 effects on MM (NCI-H28, MSTO, NCI-H2052) and non-tumor mesothelial (MET-5A) cells. We found that CpHV-1 reduced cell viability and clonogenic potential in all MM cell lines without affecting non-tumor cells, in which, indeed, we did not detect intracellular viral DNA after treatment. In particular, CpHV-1 induced MM cell apoptosis and accumulation in G0/G1 or S cell cycle phases. Moreover, CpHV-1 strongly synergized with cisplatin, the drug currently used in MM chemotherapy, and this agent combination did not affect normal mesothelial cells. Although further studies are required to elucidate the mechanisms underlying the selective CpHV-1 action on MM cells, our data suggest that the CpHV-1-cisplatin combination could be a feasible strategy against MM.

Indexed as

ApoptosisOncolytic VirotherapyAntineoplastic AgentsCell Line, TumorCell SurvivalCisplatinCombined Modality TherapyHumansMesothelioma, MalignantOncolytic VirusesVaricellovirusAntineoplastic AgentsCisplatinapoptosiscaprine herpesvirus 1 (CpHV-1)cisplatinmalignant mesothelioma (MM)oncolytic virus (OV)synergism

Identifiers

PMID34960727
PMCPMC8703924
OpenAlexW4200286724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.